A novel iminosugar UV-12 with activity against the diverse viruses influenza and dengue (Novel iminosugar antiviral for influenza and dengue)

Viruses

Volumn 7, Issue 5, 2015, Pages 2404-2427

  Warfield, Kelly L ^a   Plummer, Emily ^b   Alonzi, Dominic S ^c   Wolfe, Gary W ^d   Sampath, Aruna ^a   Nguyen, Tam ^e   Butters, Terry D ^c   Enterlein, Sven G ^f   Stavale, Eric J ^f   Shresta, Sujan ^b   Ramstedt, Urban ^a  

^a Unither Virology LLC   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Gary Wolfe Toxicology   (United States)

^e Tam Nguyen LLC   (United States)

^f Integrated BioTherapeutics   (United States)

Author keywords

Flaviviridae; Flavivirus; Glucosidase; Glycosylation; Mouse; Orthomyxoviridae; Orthomyxovirus

Indexed keywords

ALPHA GLUCOSIDASE; CYTOCHROME P450; GAMMA INTERFERON; IMINOSUGAR; IMINOSUGAR UV 12; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; OLIGOSACCHARIDE; RANTES; TRANSCRIPTION FACTOR ERG; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

AMES TEST; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DENGUE VIRUS; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; IC50; INFLUENZA VIRUS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; METABOLIC STABILITY; NONHUMAN; PLASMA HALF LIFE; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TANDEM MASS SPECTROMETRY; VIRUS LOAD; ANIMAL; DENGUE; DISEASE MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MOUSE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME;

CAVIA; FLAVIVIRIDAE; FLAVIVIRUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; IMINO SUGARS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME;

EID: 84929332289     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7052404     Document Type: Article

References (44)

1. Chang, J.; Block, T.M.; Guo, J.T. Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions. Antivir. Res. 2013, 99, 251-260
2. Dalziel, M.; Crispin, M.; Scanlan, C.N.; Zitzmann, N.; Dwek, R.A. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014, 343, 1235681
3. Norton, P.A.; Gu, B.; Block, T.M. Iminosugars as antiviral agents. In Iminosugars: From Synthesis to Therapeutic Applications; Compain, P., Martin, O.R., Eds.; John Wiley & Sons: Chichester, UK, 2007; pp. 207-224
4. Zitzmann, N.; Block, T.; Methta, A.; Rudd, P.; Burton, D.; Wilson, I.; Platt, F.; Butters, T.; Dwek, R.A. Glycosylation: Disease targets and therapy. Adv. Exp. Med. Biol. 2005, 564, 1-2
5. Mehta, A.; Zitzmann, N.; Rudd, P.M.; Block, T.M.; Dwek, R.A. Alpha-glucosidase inhibitors as potential broad based anti-viral agents. FEBS Lett. 1998, 430, 17-22
6. Sadat, M.A.; Moir, S.; Chun, T.W.; Lusso, P.; Kaplan, G.; Wolfe, L.; Memoli, M.J.; He, M.; Vega, H.; Kim, L.J.; et al. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N. Engl. J. Med. 2014, 370, 1615-1625
7. Abian, O.; Alfonso, P.; Velazquez-Campoy, A.; Giraldo, P.; Pocovi, M.; Sancho, J. Therapeutic strategies for gaucher disease: Miglustat (nb-dnj) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol. Pharm. 2011, 8, 2390-2397
8. Durantel, D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr. Opin. Investig. Drugs 2009, 10, 860-870
9. Watanabe, S.; Rathore, A.P.; Sung, C.; Lu, F.; Khoo, Y.M.; Connolly, J.; Low, J.; Ooi, E.E.; Lee, H.S.; Vasudevan, S.G. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antivir. Res. 2012, 96, 32-35
10. Bridges, C.G.; Ahmed, S.P.; Kang, M.S.; Nash, R.J.; Porter, E.A.; Tyms, A.S. The effect of oral treatment with 6-o-butanoyl castanospermine (mdl 28,574) in the murine zosteriform model of hsv-1 infection. Glycobiology 1995, 5, 249-253
11. Ruprecht, R.M.; Mullaney, S.; Andersen, J.; Bronson, R. In vivo analysis of castanospermine, a candidate antiretroviral agent. J. Acquir. Immune Defic. Syndr. 1989, 2, 149-157
12. Saito, T.; Yamaguchi, I. Effect of glycosylation and glucose trimming inhibitors on the influenza a virus glycoproteins. J. Vet. Med. Sci. 2000, 62, 575-581
13. Chang, J.; Schul, W.; Butters, T.D.; Yip, A.; Liu, B.; Goh, A.; Lakshminarayana, S.B.; Alonzi, D.; Reinkensmeier, G.; Pan, X.; et al. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antivir. Res. 2011, 89, 26-34
14. Chang, J.; Schul, W.; Yip, A.; Xu, X.; Guo, J.T.; Block, T.M. Competitive inhibitor of cellular alpha-glucosidases protects mice from lethal dengue virus infection. Antivir. Res. 2011, 92, 369-371
15. Chang, J.; Warren, T.K.; Zhao, X.; Gill, T.; Guo, F.; Wang, L.; Comunale, M.A.; Du, Y.; Alonzi, D.S.; Yu, W.; et al. Small molecule inhibitors of er alpha-glucosidases are active against multiple hemorrhagic fever viruses. Antivir. Res. 2013, 98, 432-440
16. Perry, S.T.; Buck, M.D.; Plummer, E.M.; Penmasta, R.A.; Batra, H.; Stavale, E.J.; Warfield, K.L.; Dwek, R.A.; Butters, T.D.; Alonzi, D.S.; et al. An iminosugar with potent inhibition of dengue virus infection in vivo. Antivir. Res. 2013, 98, 35-43
17. Wu, S.F.; Lee, C.J.; Liao, C.L.; Dwek, R.A.; Zitzmann, N.; Lin, Y.L. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 2002, 76, 3596-3604
18. Stavale, E.J.; Vu, H.; Sampath, A.; Ramstedt, U.; Warfield, K.L. In vivo therapeutic protection against influenza a (h1n1) oseltamivir-sensitive and resistant viruses by the iminosugar uv-4. PLOS ONE 2015, 10, e0121662
19. Pollock, S.; Dwek, R.A.; Burton, D.R.; Zitzmann, N. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS 2008, 22, 1961-1969
20. Alonzi, D.S.; Neville, D.C.; Lachmann, R.H.; Dwek, R.A.; Butters, T.D. Glucosylated free oligosaccharides are biomarkers of endoplasmic- reticulum alpha-glucosidase inhibition. Biochem. J. 2008, 409, 571-580
21. Karlsson, G.B.; Butters, T.D.; Dwek, R.A.; Platt, F.M. Effects ofthe imino sugar n-butyldeoxynojirimycin on the n-glycosylation of recombinant gp120. J. Biol. Chem. 1993, 268, 570-576
22. Olafson, R.W.; Thomas, J.R.; Ferguson, M.A.; Dwek, R.A.; Chaudhuri, M.; Chang, K.P.; Rademacher, T.W. Structures of the n-linked oligosaccharides of gp63, the major surface glycoprotein, from leishmania mexicana amazonensis. J. Biol. Chem. 1990, 265, 12240-12247
23. Alonzi, D.S.; Kukushkin, N.V.; Allman, S.A.; Hakki, Z.; Williams, S.J.; Pierce, L.; Dwek, R.A.; Butters, T.D. Glycoprotein misfolding in the endoplasmic reticulum: Identification of released oligosaccharides reveals a second er-associated degradation pathway for golgi-retrieved proteins. Cell. Mol. Life Sci. 2013, 70, 2799-2814
24. Food and Drug Administration. Guidance for Industry: S7a Safety Pharmacology Studies for Human Pharmaceuticals; Food and Drug Administration: Washington, DC, USA, 2001
25. Food and Drug Administration. Guidance for Industry: S2(r1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use; Food and Drug Administration: Washington, DC, USA, 2012
26. Perry, S.T.; Prestwood, T.R.; Lada, S.M.; Benedict, C.A.; Shresta, S. Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. J. Virol. 2009, 83, 8276-8281
27. Zellweger, R.M.; Prestwood, T.R.; Shresta, S. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 2010, 7, 128-139
28. Prestwood, T.R.; Prigozhin, D.M.; Sharar, K.L.; Zellweger, R.M.; Shresta, S. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J. Virol. 2008, 82, 8411-8421
29. Perry, S.T.; Buck, M.D.; Lada, S.M.; Schindler, C.; Shresta, S. Stat2 mediates innate immunity to dengue virus in the absence of stat1 via the type I interferon receptor. PLOSPathog. 2011, 7, e1001297
30. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175, 880-885
31. Obach, R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. DrugMetab. Dispos. 1999, 27, 1350-1359
32. Fischl, M.A.; Resnick, L.; Coombs, R.; Kremer, A.B.; Pottage, J.C., Jr.; Fass, R.J.; Fife, K.H.; Powderly, W.G.; Collier, A.C.; Aspinall, R.L.; et al. The safety and efficacy of combination n-butyl-deoxynojirimycin (sc-48334) and zidovudine in patients with HIV-1 infection and 200-500 cd4 cells/mm3. J. Acquir. Immune Defic. Synd. 1994, 7, 139-147
33. Low, J.G.; Sung, C.; Wijaya, L.; Wei, Y.; Rathore, A.P.; Watanabe, S.; Tan, B.H.; Toh, L.; Chua, L.T.; Hou, Y.; et al. Efficacy and safety of celgosivir in patients with dengue fever (celaden): A phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect. Dis. 2014, 14, 706-715
34. Hebert, D.N.; Foellmer, B.; Helenius, A. Calnexin and calreticulin promote folding, delay oligomerization and suppress degradation of influenza hemagglutinin in microsomes. EMBO J. 1996, 15, 2961-2968
35. Hebert, D.N.; Foellmer, B.; Helenius, A. Glucose trimming and reglucosylation determine glycoprotein association with calnexin in the endoplasmic reticulum. Cell 1995, 81, 425-433
36. Pan, Y.T.; Hori, H.; Saul, R.; Sanford, B.A.; Molyneux, R.J.; Elbein, A.D. Castanospermine inhibits the processing of the oligosaccharide portion of the influenza viral hemagglutinin. Biochemistry 1983, 22, 3975-3984
37. Hammond, C.; Braakman, I.; Helenius, A. Role of n-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc. Natl. Acad. Sci. USA 1994, 91, 913-917
38. Karaivanova, V.K.; Luan, P.; Spiro, R.G. Processing of viral envelope glycoprotein by the endomannosidase pathway: Evaluation of host cell specificity. Glycobiology 1998, 8, 725-730
39. Hussain, S.; Miller, J.L.; Harvey, D.J.; Gu, Y.; Rosenthal, P.B.; Zitzmann, N.; McCauley, J.W. Strain-specific antiviral activity of iminosugars against human influenza a viruses. J. Antimicrob. Chemother. 2015, 70, 136-152
40. Datema, R.; Romero, P.A.; Rott, R.; Schwarz, R.T. On the role of oligosaccharide trimming in the maturation of sindbis and influenza virus. Arch. Virol. 1984, 81, 25-39
41. Romero, P.A.; Datema, R.; Schwarz, R.T. N-methyl-1-deoxynojirimycin, a novel inhibitor of glycoprotein processing, and its effect on fowl plague virus maturation. Virology 1983, 130, 238-242
42. Kukushkin, N.V.; Easthope, I.S.; Alonzi, D.S.; Butters, T.D. Restricted processing of glycans by endomannosidase in mammalian cells. Glycobiology 2012, 22, 1282-1288
43. Chen, S.T.; Lin, Y.L.; Huang, M.T.; Wu, M.F.; Cheng, S.C.; Lei, H.Y.; Lee, C.K.; Chiou, T.W.; Wong, C.H.; Hsieh, S.L. Clec5a is critical for dengue-virus-induced lethal disease. Nature 2008, 453, 672-676
44. Platt, F.M.; Reinkensmeier, G.; Dwek, R.A.; Butters, T.D. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with n-butyldeoxynojirimycin. J. Biol. Chem. 1997, 272, 19365-19372